Interim CEO, President, Avid Bioservices
WHY: Pharma vet running $300M-valued contract drug manufacturer, previously called Peregrine Pharmaceuticals.
RECENT: Named interim CEO in May, succeeding Roger Lias. Company no longer developing own cancer drugs, focus on contract work.
NOTABLE: Served as president and CEO of Ajinomoto Athea, board member of Tempo Therapeutics. Bachelor’s degree, microbiology and immunology, Miami University.
